ACLX - Arcellx Inc

Arcellx, Inc., a clinical-stage biotechnology company, is engaged in the development of various immunotherapies for patients with cancer and other incurable diseases. The company is headquartered in Gaithersburg, Maryland.

52W High

$107.37

52W Low

$47.86

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.27

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-6.52

EV/Revenue (<3 favorable)

63.74

P/S (TTM) (<3 favorable)

70.77

P/B (<3 favorable)

10.28

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

13.45%

Institutions (25–75% balanced)

106.11%

Shares Outstanding

55,459,000

Float

37,268,400

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

56,979,000

Gross Profit (TTM)

-115,271,000

EPS (TTM)

-3.41

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-7.77%

ROE (TTM) (>15% strong)

-0.43%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.72

Momentum

Bearish momentum

Value

1.4853

1.1919

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025